Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is initiating a Phase 2 study ...

Broadcom on Thursday said its AI revenue will double in the current quarter, but shares slumped as investors focused on ...

From a technical perspective, Regeneron (REGN) is looking like an interesting pick, as it just reached a key level of support. REGN recently overtook the 20-day moving average, and this suggests a ...

Apellis Pharmaceuticals, Inc. faces a Sell rating amid revenue stagnation, Syfovre challenges, and uncertain long-term profit ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron (REGN) to $768 from $767 and keeps an Equal Weight rating on the ...

Citron Research says a stock is being "deeply mispriced" by investors, assigning a price target more than double its current levels.

The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...

Immix Biopharma is advancing NXC-201, showing 95% complete/near-complete response rates and superior safety. Learn why IMMX ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...